Deep dissection of the antiviral immune profile of patients with COVID-19.

Autor:	Atanackovic D; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA. datanackovic@som.umaryland.edu.; Department of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA. datanackovic@som.umaryland.edu., Avila SV; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Lutfi F; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., de Miguel-Perez D; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Fan X; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Sanchez-Petitto G; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Vander Mause E; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Siglin J; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Baddley J; Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Mannuel HD; Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Baltimore Veterans Affairs Medical Center, Baltimore, MD, USA., Alkhaldi H; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Hankey KG; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Lapidus R; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Kleinberg M; Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Rabin J; R. Adams Cowley Shock Trauma Center, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA., Shanholtz C; Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA., Rolfo C; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Rapoport AP; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Dahiya S; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Luetkens T; Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA.
Jazyk:	angličtina
Zdroj:	Communications biology [Commun Biol] 2021 Dec 16; Vol. 4 (1), pp. 1389. Date of Electronic Publication: 2021 Dec 16.
DOI:	10.1038/s42003-021-02852-1
Abstrakt:	In light of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants potentially undermining humoral immunity, it is important to understand the fine specificity of the antiviral antibodies. We screened 20 COVID-19 patients for antibodies against 9 different SARS-CoV-2 proteins observing responses against the spike (S) proteins, the receptor-binding domain (RBD), and the nucleocapsid (N) protein which were of the IgG1 and IgG3 subtypes. Importantly, mutations which typically occur in the B.1.351 "South African" variant, significantly reduced the binding of anti-RBD antibodies. Nine of 20 patients were critically ill and were considered high-risk (HR). These patients showed significantly higher levels of transforming growth factor beta (TGF-β) and myeloid-derived suppressor cells (MDSC), and lower levels of CD4 + T cells expressing LAG-3 compared to standard-risk (SR) patients. HR patients evidenced significantly higher anti-S1/RBD IgG antibody levels and an increased neutralizing activity. Importantly, a large proportion of S protein-specific antibodies were glycosylation-dependent and we identified a number of immunodominant linear epitopes within the S1 and N proteins. Findings derived from this study will not only help us to identify the most relevant component of the anti-SARS-CoV-2 humoral immune response but will also enable us to design more meaningful immunomonitoring methods for anti-COVID-19 vaccines. (© 2021. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF